The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases
Clinical trial NCT05181397 · UNKNOWN
Trial details
- NCT number
- NCT05181397
- Sponsor
- Peking Union Medical College Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-22
- Primary completion
- 2022-09-01
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.